Rationale for very high-dose chemotherapy with peripheral blood stem cell support in advanced ovarian cancer.
Although significant progress has been made in the management of advanced ovarian cancer, the majority of patients continue to die of this disease. Most advanced ovarian cancer patients present sub-optimal residual tumour after primary surgery and their prognosis is very poor since residual disease has been confirmed as the major factor predicting response to chemotherapy and survival. Therefore, it seems worth developing treatment modalities that can produce a longer remission period. In this short review, the authors summarize the clinical and experimental evidence supporting the usefulness of high-dose chemotherapy with autologous peripheral blood stem cell transplantation in advanced ovarian cancer.
Panici
P B
PB
Divisione di Ginecologia, Università Cattolica, Roma, Italy.
Scambia
G
G
Baiocchi
G
G
Laurelli
G
G
Greggi
S
S
Battaglia
F
F
Ragusa
G
G
Salerno
G
G
Gallo
A
A
Cento
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001804:Blood Transfusion, Autologous / Q000379:methods*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate